Abstracts Archive - Page 321 of 2425 - ACR Meeting Abstracts

Abstract Number: 1354 • ACR Convergence 2023
The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus
Ceshae Harding¹, Amanda Eudy², Catherine Sims¹, Cuoghi Edens³, Mehret Birru Talabi⁴, Rosalind Ramsey-Goldman⁵, Laura Neil¹ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³University of Chicago, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Duke University, Chapel Hill, NC
Background/Purpose: Mental health conditions are the leading cause of maternal mortality across most of the United States. Among individuals with SLE, pregnancy intention has been…
Abstract Number: 1322 • ACR Convergence 2023
Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
Christoph Burkart, Clara Polizzi, Lisa Eide, Max Pastenes, David Siefker and Leslie Nangle, aTyr Pharma, San Diego, CA
Background/Purpose: Efzofitimod, a novel immunomodulator, has shown clinical proof-of-concept in a Phase 1b/2a clinical trial in patients with pulmonary sarcoidosis and is currently enrolling a…
Abstract Number: 1364 • ACR Convergence 2023
Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴, Rebecca Jacobson¹ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: We evaluated the role of maternal 25(OH)-vitamin D in adverse pregnancy outcomes in systemic lupus erythematosus (SLE). Methods: We used a longitudinal cohort that…
Abstract Number: 1368 • ACR Convergence 2023
Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s
Benjamin A Fisher¹, Linda Stone², Jessica Marvel³, Pushpendra Goswami⁴, Monia Steenackers⁴, Gayle Kenney⁴, Chiara Perella⁵, Wolfgang Hueber⁴, Chloe Howse⁶, Elizabeth Gargon⁶, Aishwarya Chohan⁶, Megan Mayhew⁶ and Nicola Williamson⁶, ¹University of Birmingham, Birmingham, United Kingdom, ²The British Sjogren’s Syndrome Association, Birmingham, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Riehen, Switzerland, ⁶Adelphi Values Patient-Centered Outcomes, Bollington, United Kingdom
Background/Purpose: Sjögren's is a heterogenous chronic auto-immune disease, characterized by excessive dryness of the eyes and mouth, as well as systemic complications which can significantly…
Abstract Number: 1355 • ACR Convergence 2023
Delivering Care for Pregnant Women with Rheumatic and Musculoskeletal Diseases in Ireland: Current Challenges and Practices
Rebecca O'Farrell¹, Sinead Maguire², Louise Moore³, Kieran Murray⁴, Áine Gorman⁵, Elisabeth Ball⁶, Claire Riddell⁶, Madeline O'Neill⁷, Natasha Jordan⁸, Barry O'Shea⁹, Douglas Veale¹⁰, Suzanne Donnelly¹¹, Grainne Murphy¹² and Gillian Fitzgerald¹³, ¹Department of Rheumatology, Galway, Dublin, Ireland, ²Toronto Western Hospital, Toronto, ON, Canada, ³Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Harold's Cross,, Ireland, ⁴University Hospital Limerick, Limerick, Ireland, ⁵Royal United Hospital, Bath, United Kingdom, ⁶Belfast Health and Social Care Trust, Belfast, United Kingdom, ⁷Our Lady's Hospice, Harold's Cross, Dublin, Ireland, ⁸Addenbrooke's Hospital, Cambridge, United Kingdom, ⁹St James's Hospital, Dublin, Ireland, ¹⁰St.Vincent's University Hosp, Dublin, Ireland, ¹¹Mater Misericordiae University Hospital, Dublin, Ireland, ¹²Cork University Hospital, Cork, Ireland, ¹³University Hospital Galway, Galway, Ireland
Background/Purpose: Rheumatic disease frequently affects women of childbearing age. Women with pre-existing rheumatic disease who are planning a pregnancy or develop these conditions during pregnancy…
Abstract Number: 1371 • ACR Convergence 2023
Are Ultrasound Salivary Parenchymal Abnormalities More Severe in Primary Sjögren Patients with a Higher Disease Duration ? A Cross-sectional International Study
Alice TISON¹, sandrine jousse joulin², Maëlys Consigny³, Philipp Moog⁴, Benedikt Hofauer⁵, Eric Hachulla⁶, Christophe Lamotte⁷, JACQUES MOREL⁸, Gael Mouterde⁹, Vera Milic¹⁰, Hendrika Bootsma¹¹, Alja Stel¹², Benjamin A Fisher¹³, Mark Maybury¹⁴, Alan Baer¹⁵, Dana Direnzo¹⁶, Hae-Rim Kim¹⁷, Hong Ki Min¹⁸, Shin-Seok Lee¹⁹, Sung-Eun Choi¹⁹, Guillermo CARVAJAL ALEGRIA²⁰, Sylvie Boisramé²¹, Dewi Guellec²², Divi Cornec²³, Malin Jonsson²⁴, Daniel Hammenfors²⁵, Alain SARAUX²⁶ and Valerie Devauchelle²⁷, ¹CHU de la Cavale Blanche, Brest, France, ²Rheumatology, CHU Brest, Brest, France, ³Biostatistics, CHU Brest, Brest, France, ⁴Rheumatology, CHU Munich, Munich, Germany, ⁵Otolaryngology, CHU Munich, Munich, Germany, ⁶University of Lille, Lille, France, ⁷Internal Medicine and Clinical Immunology, CHU Lille, Lille, France, ⁸Protocole thérapeutique immuno-rhumatologie, Montpellier, France, ⁹CHU Lapeyronie, Montpellier, France, ¹⁰Rheumatology, University of Belgrade, Medical School, Belgrade, Serbia, ¹¹Department of Rheumatology, University Medical Centre Groningen, Groningen, Netherlands, ¹²Rheumatology and clinical immunology, University Medical Center Groningen, Groningen, Netherlands, ¹³University of Birmingham, Birmingham, United Kingdom, ¹⁴Rheumatology, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶University of Pennsylvania, Bala Cynwyd, PA, ¹⁷Rheumatology, Konkuk University Medical Center, Seoul, South Korea, ¹⁸Konkuk University School of Medicine, Seoul, South Korea, ¹⁹Chonnam National University Medical School & Hospital, Gwangju, South Korea, ²⁰CHRU de Tours, Tours, France, ²¹Ondontology, CHU Brest, France, Brest, France, ²²CHU de Brest, Brest, France, ²³University of Brest, Brest, France, ²⁴Clinical dentistry, University of Bergen, Bergen, Norway, Bergen, Norway, ²⁵Rheumatology, Haukeland University Hospital, Bergen, Norway, ²⁶CHU Brest, Brest, France, ²⁷UBO, Brest, France
Background/Purpose: Salivary gland ultrasonography (SGUS) is commonly used in primary Sjögren Disease (pSD) as a diagnostic tool. It could also be used to monitor disease…
Abstract Number: 1361 • ACR Convergence 2023
Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², Sho Fukui³, Ayako Kitada¹, Naoto Yokogawa⁴ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Tama Medical Center, Fuchu-shi, Japan, ³Brigham and Women's Hospital, Boston, MA, ⁴Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan
Background/Purpose: Achieving remission is one of the treatment targets in the lupus care and it is also important in preventing the prevalence of adverse pregnancy…
Abstract Number: 1334 • ACR Convergence 2023
Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses
Marina Birck¹, Luck Lukusa², Michal Abrahamowicz³, Gilles Boire⁴, Denis Choquette⁵, Walter P. Maksymowych⁶ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²RI-MUHC, Montreal, QC, Canada, ³McGill University, Verdun, QC, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment safety, particularly malignancy and infections, is an important issue for biologics; hence, surveillance and analyses comparing biosimilar versus bio-originator use in the real…
Abstract Number: 1367 • ACR Convergence 2023
Novel Autoantibodies Might Circumvent the Need for Labial Biopsy in a Subset of Seronegative Sjögren’s Disease Patients
Maxwell Parker¹, Zihao Zheng², Michael Lasarev³, Roxana Alexandridis³, Michael Newton³, Miriam Shelef³ and Sara McCoy⁴, ¹University of Wisconsin-Madison, Madison, WI, ²Google, Sunnyvale, CA, ³University of Wisconsin, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Middleton, WI
Background/Purpose: Sjögren's disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients…
Abstract Number: 1336 • ACR Convergence 2023
Adalimumab and Etanercept Serum Levels in Rheumatoid Arthritis Patients with and Without a Disease Flare During Tapering
Zohra Layegh¹, Femke Hooijberg², Floris loeff³, lisanne Dijk³, Gaelle vaz³, Theo Rispens³, radboud J.e.m. Dolhain⁴, Gertjan Wolbink⁵ and Pascal de Jong¹, ¹Erasmus medical center, Rotterdam, Netherlands, ²Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Dr. Jan van Breemenstraat 2, 1056 AB, Amsterdam, Netherlands, ³Sanquin Diagnostic Service, Biologics Laboratory, Amsterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: Due to the improved management strategies and availability of biologic disease-modifying antirheumatic drugs (bDMARDs), ~60% of the rheumatoid arthritis (RA) patients will achieve sustained…
Abstract Number: 1376 • ACR Convergence 2023
SJOGRENSER Registry: Prospective Evaluation of a Cohort of Patients with Primary Sjögren’s Syndrome After 8 Years of Follow-up
Mónica Fernández-Castro¹, Zulema Plaza², Jose Rosas³, Victor Martinez-Taboada⁴, Alejandro Olivé⁵, Raúl Menor-Almagro⁶, SARA MANRIQUE⁷, Ruth López-González⁸, Celia Erausquin⁹, Antonio Naranjo⁹, Rocío Caño-Alameda¹⁰, Silvia Gómez-Sabater¹⁰, Jesús Alberto García Vadillo¹¹, Belen Serrano Benavente¹², Sheila Melchor¹³, Paula V. Estrada-Alarcón¹⁴, Angel Garcia-Aparicio¹⁵, Cristina Bohorquez¹⁶, Enrique Júdez¹⁷, Ximena Larco¹⁸, Javier Loricera¹⁹, Nerea Alcorta Lorenzo²⁰, Beatriz Paredes Romero²¹, Jorge González Martín²², María Ángeles Blázquez Cañamero²³, Consuelo Ramos-Giráldez²⁴, Fernando Alonso²⁵, Marta Domínguez²⁶ and Jose Luis Andreu-Sánchez²⁷, ¹Rheumatology Department Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain, ²Universidad Autónoma de Madrid, Madrid, Spain, ³Hospital Marina Baixa, Alicante, Spain, ⁴Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department Hospital Germans Trias i Pujol, Badalona, Spain, ⁶Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ⁷Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁸Rheumatology Department Hospital Virgen de la Concha, Zamora, Spain, ⁹Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁰Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹¹Rheumatology Department Hospital de la Princesa, Madrid, Spain, ¹²Rheumatology Department Hospital Gregorio Marañón, Madrid, Spain, ¹³Rheumatology Department Hospital Doce de Octubre, Madrid, Spain, ¹⁴Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹⁵Hospital Universitario de Toledo, Toledo, Spain, ¹⁶Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ¹⁷Rheumatology Department Hospital de Albacete, Albacete, Spain, ¹⁸Rheumatology Department Hospital de León, León, Spain, ¹⁹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²⁰University Hospital Donostia, San Sebastian, Spain, ²¹Rheumatology Department Hospital Infanta Sofía, San Sebastian de los Reyes, Spain, ²²Rheumatology Department Hospital Madrid Norte Sanchinarro, Madrid, Spain, ²³Rheumatology Department Hospital Ramon y Cajal, Madrid, Spain, ²⁴Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, ²⁵Spanish Society of Rheumatology, Madrid, Spain, ²⁶Sociedad Española de Reumatología, Madrid, Spain, ²⁷Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Describe the evolution of patients with Sjögren's syndrome (SS) in relation to the appearance of new systemic manifestations and disease activity, as well as…
Abstract Number: 1379 • ACR Convergence 2023
Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome
Kenneth Der¹, Ryan Crass², Brendan Smith³, Wonkyung Byon⁴, Yan Xin⁵ and Jiayin Huang⁶, ¹Horizon Therapeutics, Danville, CA, ²Apellis Pharmaceuticals, Michigan, ³A2-Ai, Michigan, ⁴Amador Bioscience, Michigan, ⁵Horizon Therapeutics, South San Francisco, CA, ⁶Horizon Therapeutics, Chicago, IL
Background/Purpose: Sjögren's (SjS) is a chronic, systemic autoimmune disease caused by aberrant activation and infiltration of lymphocytes. Dazodalibep (DAZ), a novel non-antibody biologic antagonist of…
Abstract Number: 1372 • ACR Convergence 2023
Obinutuzumab Efficacy and Tolerance in Patients with Auto-Immune Diseases Immunized Against Rituximab
Mathilde Pezot¹, Gaetane Nocturne², Rakiba Belkhir¹, Julien Henry¹, Stephan Pavy¹, Raphaele Seror³, Xavier Mariette⁴ and Samuel Bitoun⁵, ¹Rheumatology Department, Université Paris-Saclay, INSERM U1184, Hôpital Bicêtre, APHP, FHU CARE, Le Kremlin-Bicêtre, France, ²APHP, Le Kremlin-Bicêtre, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁵CHU Bicêtre APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Among patients with auto-immune diseases (AID) treated with Rituximab (RTX), anti-drug antibodies (ADAb) leading to inefficacy and infusion reactions (Wincup and al., Ann Rheum…
Abstract Number: 1384 • ACR Convergence 2023
Functional Status by Sex and Socioeconomic Status in Axial Spondyloarthritis
Rachael Stovall¹, Jing Li¹, zara izadi¹, Lianne Gensler², Gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹University of California San Francisco, San Francisco, CA, ²University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA, ⁴University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA
Background/Purpose: Women with axial spondyloarthritis (axSpA) tend to have worse patient reported outcomes compared to men. Non-U.S. studies have evaluated functional status (FS) by sex…
Abstract Number: 1370 • ACR Convergence 2023
Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration
Eui-Jong Kwon¹, Jin-Sil Park², Ha Yeon Jeong³, Hye Yeon Kang⁴, JeongWon Choi³, Mi-La Cho³ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary's Hospital, Seocho-gu, South Korea, ²The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, ³Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Sjogren’s syndrome (SS) is a systemic autoimmune disease characterized by infiltration of lymphocytes into the exocrine gland resulting in progressive lacrimal and salivary estruction…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].